In summary, in this study, we demonstrate that fedratinib suppresses proliferation, migration, and apoptosis resistance in esophageal squamous cell carcinoma through inhibition of the JAK2/STAT3 signaling pathway. Here, JAK2 is linked to esophageal squamous cell carcinoma.